Data were not produced by the current Meta-Analysis and only the original authors could make them available on an individual basis. These data are held in the repository of the Infectious Diseases Data Observatory ([IDDO.org](http://IDDO.org)). IDDO promotes data sharing and data re-use to generate new evidence that improves health and understanding of disease. Requests to access data can be submitted by email to <dataccess@iddo.org> via the Data Access Application Form available at [IDDO.org/accessing-data](http://IDDO.org/accessing-data). If eligible, requests will be reviewed by the IDDO Data Access Committee to ensure that use of data protects the interests of the participants and researchers according to the IDDO principles of data sharing (see <https://www.iddo.org/data-sharing/accessing-data>).

Introduction {#sec005}
============

The global schistosomiasis control strategy relies upon preventive chemotherapy with praziquantel, primarily targeting school-age children. In moderate- and high-risk communities, treatment is also extended to adults \[[@pntd.0008277.ref001]\]. Of note, preschool-age children contribute a considerable fraction of the total burden of schistosomiasis \[[@pntd.0008277.ref002]--[@pntd.0008277.ref004]\]. The current World Health Organization (WHO) guidelines are that preschool-age children should be treated on a case-by-case basis upon diagnosis of infection due to a lack of an age-appropriate formulation of praziquantel \[[@pntd.0008277.ref005]\]. WHO is considering the inclusion of preschool-age children in preventive chemotherapy with praziquantel, should an appropriate formulation of praziquantel become available \[[@pntd.0008277.ref005]--[@pntd.0008277.ref007]\]. The reason is that the current formulation (large, bitter tasting 600 mg tablets), although often crushed and dissolved in practice, is unsuited for use in young children, and hence, efforts are underway to develop an orally dispersible tablet formulation for young children \[[@pntd.0008277.ref008], [@pntd.0008277.ref009]\]. Evidence of efficacy and safety of praziquantel in preschool-age children is limited \[[@pntd.0008277.ref005]\], and it is unclear whether they should receive the same dose (i.e., oral administration at a single dose of 40 mg/kg body weight) as their school-age counterparts, adolescents, and adults \[[@pntd.0008277.ref010]\].

To address this issue, we analyzed data from clinical trials and epidemiologic studies that enrolled preschool- and school-age children who were treated with praziquantel at a single 40 mg/kg oral dose, for which data were available at the individual participant level. This information is important both for treatment recommendations and for adapting the strength of praziquantel to be used in pediatric formulation.

Methods {#sec006}
=======

Ethics statement {#sec007}
----------------

This is a secondary analysis of published work. Ethical approval and written (or oral) informed consent have been reported in the original papers \[[@pntd.0008277.ref005], [@pntd.0008277.ref011]--[@pntd.0008277.ref030]\].

Datasets {#sec008}
--------

Based on a scoping paper \[[@pntd.0008277.ref031]\], the WHO Special Programme for Research and Training in Tropical Diseases (TDR) and the Department of Control of Neglected Tropical Diseases at WHO contacted investigators for the availability of suitable patient datasets from studies that enrolled preschool-age children. The investigators of 23 clinical studies \[[@pntd.0008277.ref005], [@pntd.0008277.ref011]--[@pntd.0008277.ref030]\] agreed to share data with the specific purpose of pooled analyses aimed at answering the PICO (population, intervention, control, and outcome) question below. The datasets were curated in order to allow for the pooled analysis. One article \[[@pntd.0008277.ref018]\] contained two different studies, which were analyzed separately. Subsequently, studies were further assessed as to their eligibility for inclusion in the analysis (whole study or subset of participants). In this dataset, studies are identified by the name of the main data contributor and the year the study was conducted.

PICO question {#sec009}
-------------

In preschool-age children, is praziquantel given at 40 mg/kg body weight in a single oral dose as efficacious as it is in school-age children in reducing *Schistosoma* infection (measured as egg counts in stool or urine)?

Study and patient inclusion criteria {#sec010}
------------------------------------

The following inclusion criteria were employed: (i) treatment with praziquantel 40 mg/kg body weight; (ii) participant's age 0--14 years; (iii) confirmed infection with *Schistosoma mansoni*, *S*. *haematobium*, or *S*. *japonicum*, as determined by the presence of eggs in stool or urine; and (iv) treatment outcome assessed at follow-up visit between 21 and 60 days post-treatment.

Assessment of methodological quality {#sec011}
------------------------------------

Key characteristics of studies were extracted from the published articles. The methodologic quality was assessed through the Cochrane Collaboration's \[[@pntd.0008277.ref032]\] risk of bias table, including items such as random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective reporting (reporting bias). We also prepared funnel plots to check for publication bias, stratified by *Schistosoma* species.

Assessment of heterogeneity {#sec012}
---------------------------

We investigated heterogeneity by examining the forest plots, and carried out sensitivity analyses by calculating the pooled mean difference of individual egg reduction rate (ERR) between preschool- and school-age children.

Assessment of reporting bias {#sec013}
----------------------------

We compared studies included in this analysis with those identified by a prior scoping review \[[@pntd.0008277.ref031]\]. However, only studies for which individual participant-level data were made available could be included in the present analysis.

Statistical methods {#sec014}
-------------------

### Summarizing infection intensity {#sec015}

The arithmetic mean (AM) eggs per gram of stool (EPG) was calculated at pre- and post-treatment for *S*. *mansoni* by multiplying the mean individual fecal egg counts (FECs) obtained by a single, duplicate, or quadruplicate Kato-Katz thick smears (41.7 mg) by a factor of 24 \[[@pntd.0008277.ref033], [@pntd.0008277.ref034]\]. For *S*. *haematobium*, egg counts were presented as eggs per 10 ml of urine \[[@pntd.0008277.ref034]\].

### Measuring efficacy {#sec016}

Drug efficacy was expressed as AM egg reduction rate (ERR) (the difference in AM egg counts between pre- and post-treatment assessments), cure rate (CR, proportion of cases with zero egg counts post-treatment), and mean of individual ERR, with 95% confidence intervals (CIs). Individual ERRs were calculated as the ratio of the difference between the pre- and post-treatment EPG or eggs per 10 ml urine, multiplied by 100. In this analysis, no change or increase in egg counts post-treatment indicates an ERR = 0 (no reduction). CIs were determined using a bootstrap resampling method (with replacement) over 1,000 replicates. This methodology has been described in greater detail elsewhere \[[@pntd.0008277.ref035]\]. According to WHO guidelines, the reference target efficacy for AM-ERR is ≥95% \[[@pntd.0008277.ref036]\].

The distribution of the individual ERRs was plotted by using histograms of the frequencies and scatterplot of the cumulative frequencies as 'centiles plots'. Forest plots were utilized to visualize mean individual ERRs by age categories. Results are presented separately by *Schistosoma* species.

### Statistical analyses {#sec017}

Modeling of baseline log-transformed egg counts was performed with age categories and country as fixed factors in a general linear model, and with country as a random factor in a mixed model. Modeling of the individual ERRs was carried out through a general linear model and mixed models. Separate models were fitted for *S*. *mansoni* and *S*. *haematobium*.

In the general linear model, the level of infection at baseline was included as covariate (log-transformed baseline EPG for *S*. *mansoni* and eggs per 10 ml of urine for *S*. *haematobium*). Fixed variables were country, participant's sex, and three age categories: (i) 0 to \<6 years; (ii) 6 to \<10 years; and (iii) 10--14 years to more accurately reflect the age-range of the included studies (see below), or preschool-age (0 to \<6 years) versus school-age children (6--14 years). Mixed models were further fitted with a random effect on the country. Sensitivity analyses were conducted with the same models by removing the baseline log-transformed egg counts.

Pairwise differences (with a Tukey adjustment) in least square means (LSM) were performed for each of the age groups. This post-hoc comparison was allowed by the implicit network of possible preschool- and school-age children comparisons across all studies ([S1 Fig](#pntd.0008277.s011){ref-type="supplementary-material"}) \[[@pntd.0008277.ref037], [@pntd.0008277.ref038]\].

All tests were two-tailed and a p-value of 5% was deemed statistically significant. Calculations and analyses were performed by using Revman version 5.3.5 (The Nordic Cochrane Centre; Copenhagen, Denmark) (The Cochrane Collaboration, 2014) and SAS system version 9.3 (SAS Institute; Cary, United States of America).

Safety was assessed using reported adverse events (AEs), classified as mild, moderate, or severe. We extrapolated the number of patients exposed and assessed for safety at 4 and 24 hours post-treatment and at the end of follow-up and calculated the frequency of those with at least one AE. We also report the total number and type of AEs for each age-category and by severity.

The PRISMA guidelines were used and followed for reporting the current work. The PRISMA checklist is attached as supplementary material.

Results {#sec018}
=======

Data were available from 23 studies with children treated either for *S*. *mansoni*, *S*. *haematobium*, or *S*. *japonicum* infection with single 40 mg/kg oral praziquantel ([Table 1](#pntd.0008277.t001){ref-type="table"} and [S1 Table](#pntd.0008277.s001){ref-type="supplementary-material"}, including diagnostic approach used). The study flowchart (overall and by age-group; preschool- versus school-age children) is presented in [Fig 1](#pntd.0008277.g001){ref-type="fig"}. Details by study and age-group (preschool- versus school-age) are summarized in [Table 2](#pntd.0008277.t002){ref-type="table"}.

![Study flowchart (PSAC: preschool-age children; SAC: school-age children).](pntd.0008277.g001){#pntd.0008277.g001}

10.1371/journal.pntd.0008277.t001

###### Characteristics of available datasets and numbers of participants enrolled and included in the meta-analysis (0% analysed indicate excluded studies with 0% analysed).

![](pntd.0008277.t001){#pntd.0008277.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year of study \[Ref.\]                          Country         Total enrolled   Follow-up duration (days)   Dose (mg/kg)   Species               Enrolled (age 0 to \< 6 years)   Enrolled\               Enrolled\              \% analysed\   Reason for exclusion
                                                                                                                                                                                             (age 6 to \<10 years)   (age 10 to 14 years)   of enrolled    
  ------------------------------------------------------- --------------- ---------------- --------------------------- -------------- --------------------- -------------------------------- ----------------------- ---------------------- -------------- ----------------------------------------------------------------------------------------
  **Coulibaly, 2011 \[[@pntd.0008277.ref012]\]**          Côte d'Ivoire   53               21                          40             *S*. *mansoni*\       53                                                                              100%           
                                                                                                                                      *S*. *haematobium*                                                                                                   

  **Coulibaly, 2017 \[[@pntd.0008277.ref013]\]**          Côte d'Ivoire   84               21                          20\            *S*. *mansoni*        40                               22                      21                     96%            Dose = 20 & 60 mg/kg\
                                                                                                                       40\                                                                                                                                 and placebo excluded
                                                                                                                       60                                                                                                                                  

  **Coulibaly, 2018 \[[@pntd.0008277.ref014]\]**          Côte d'Ivoire   346              21                          20\            *S*. *haematobium*    170                              112                     56                     98%            Dose = 20 & 60 mg/kg and placebo excluded
                                                                                                                       40\                                                                                                                                 
                                                                                                                       60                                                                                                                                  

  **Garba, 2007 \[[@pntd.0008277.ref015]\]**              Niger           659              42                          40             *S*. *mansoni*\                                        370                     289                    83%            
                                                                                                                                      *S*. *haematobium*                                                                                                   

  **Tohon, 2008 \[[@pntd.0008277.ref039]\]**              Niger           877              21                          40             *S*. *haematobium*                                     209                     211                    83%            

  **Garba, 2013 \[[@pntd.0008277.ref016]\]**              Niger           243              42                          40             *S*. *mansoni*\       243                                                                             95%            
                                                                                                                                      *S*. *haematobium*                                                                                                   

  **N'Goran, 2000 \[[@pntd.0008277.ref020]\]**            Côte d'Ivoire   354              52                          80             *S*. *haematobium*    5                                174                     129                    0%             Dose = 80 mg/kg

  **Landouré, 2006 \[[@pntd.0008277.ref018]\]**           Mali            415              365                         40             *S*. *mansoni*\                                        413                     553                    0%             Follow-up \>60 days
                                                                                                                                      *S*. *haematobium*                                                                                                   

  **Landouré, 2009 \[[@pntd.0008277.ref018]\]**           Mali            415              182                         40             *S*. *mansoni*\       409                                                                             0%             Follow-up \>60 days
                                                                                                                                      *S*. *haematobium*                                                                                                   

  **Garba, 1996 \[[@pntd.0008277.ref017]\]**              Niger           560              60                          40             *S*. *haematobium*    77                               86                      76                     63%            

  **Mutapi, 2010 \[[@pntd.0008277.ref019]\]**             Zimbabwe        535              42                          40             *S*. *mansoni*\       132                              351                     83                     30%            
                                                                                                                                      *S*. *haematobium*                                                                                                   

  **Campagne, 2008 \[[@pntd.0008277.ref011]\]**           Niger           114              30                          40             *S*. *mansoni*\       1                                37                      66                     87%            
                                                                                                                                      *S*. *haematobium*                                                                                                   

  **Olds, 1999 \[[@pntd.0008277.ref021]\]**               Kenya           415              45                          40             *S*. *haematobium*    2                                49                      67                     100%           

  **Olliaro, 2007 \[[@pntd.0008277.ref022]\]**            Brazil\         856              21                          40\            *S*. *mansoni*\                                                                534                    36%            *S*. *japonicum* (Philippines, no preschool-age children) and dose = 60 mg/kg excluded
                                                          Mauritania\                                                  60             *S*. *haematobium*\                                                                                                  
                                                          Philippines                                                                 *S*.*japonicum*                                                                                                      

  **Raso, 2004 \[[@pntd.0008277.ref023]\]**               Mali            545              42                          40             *S*. *mansoni*        4                                12                      22                     100%           

  **Sacko, 2009 \[[@pntd.0008277.ref005]\]**              Mali            415              180                         40             *S*. *mansoni*\       415                                                                             0%             Follow-up \>60 days
                                                                                                                                      *S*. *haematobium*                                                                                                   

  **Scherrer, 2007 \[[@pntd.0008277.ref024]\]**           Côte d'Ivoire   49               20                          40             *S*. *mansoni*        6                                22                      21                     100%           

  **Sousa-Figueiredo, 2012 \[[@pntd.0008277.ref025]\]**   Uganda          880              21                          6040           *S*. *mansoni*        693                              187                                            35%            

  **Stete, 2010 \[[@pntd.0008277.ref026]\]**              Côte d'Ivoire   545              21                          40             *S*. *haematobium*    1                                20                      56                     100%           

  **Utzinger, 1997 \[[@pntd.0008277.ref027]\]**           Côte d'Ivoire   209              28                          40             *S*. *mansoni*                                         27                      56                     100%           

  **Utzinger, 1998 \[[@pntd.0008277.ref028]\]**           Côte d'Ivoire   253              28                          60             *S*. *mansoni*                                         129                     124                    0%             Dose = 60 mg/kg

  **Wami, 2014 \[[@pntd.0008277.ref029]\]**               Zimbabwe        303              84                          40             *S*. *mansoni*\       109                              148                     46                     0%             Follow-up \>60 days
                                                                                                                                      *S*. *haematobium*                                                                                                   

  **Xu, 2007 \[[@pntd.0008277.ref030]\]**                 China           880              90                          40             *S*. *japonicum*      1                                                        5                      0%             *S*. *japonicum* only one preschool-age child

  **TOTAL**                                               ** **           **10,005**                                                                        **2,361**                        **2,368**               **2,415**                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

10.1371/journal.pntd.0008277.t002

###### Number of subjects in the 16 studies enrolled and analysed.

![](pntd.0008277.t002){#pntd.0008277.t002g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year \[Ref.\]                              Enrolled PSAC   Enrolled SAC   Enrolled PSAC+SAC   Evaluable\   Evaluable\   Evaluable PSAC+SAC   With follow-up PSAC   With follow-up SAC   With follow-up PSAC+SAC
                                                                                                        PSAC         SAC                                                                          
  -------------------------------------------------- --------------- -------------- ------------------- ------------ ------------ -------------------- --------------------- -------------------- -------------------------
  Coulibaly 2011 \[[@pntd.0008277.ref012]\]          53              0              53                  53                        53                   53                                         53

  Coulibaly 2017 \[[@pntd.0008277.ref013]\]          40              43             83                  38           42           80                   38                    42                   80

  Coulibaly 2018 \[[@pntd.0008277.ref014]\]          170             168            338                 37           37           74                   37                    37                   74

  Garba 2007 \[[@pntd.0008277.ref015]\]              0               659            659                              659          659                                        549                  549

  Garba 2009 \[[@pntd.0008277.ref017]\]              0               420            420                              360          360                                        347                  347

  Garba 2013 \[[@pntd.0008277.ref016]\]              243             0              243                 243                       243                  231                                        231

  Garba 1996 \[[@pntd.0008277.ref017]\]              77              162            239                 114          228          342                  61                    160                  221

  Mutapi 2010 \[[@pntd.0008277.ref019]\]             132             434            566                 101          434          535                  21                    149                  170

  Campagne, 2008 \[[@pntd.0008277.ref011]\]          1               103            104                              100          100                                        90                   90

  Olds, 1999 \[[@pntd.0008277.ref021]\]              2               116            118                 2            116          118                  2                     116                  118

  Olliaro 2007 \[[@pntd.0008277.ref022]\]            0               534            534                              190          190                                        190                  190

  Raso 2004 \[[@pntd.0008277.ref023]\]               4               34             38                  4            34           38                   4                     34                   38

  Scherrer 2007 \[[@pntd.0008277.ref024]\]           6               43             49                  6            43           49                   6                     43                   49

  Sousa-Figueiredo 2012 \[[@pntd.0008277.ref025]\]   693             187            880                 395          128          523                  211                   94                   305

  Stete 2010 \[[@pntd.0008277.ref026]\]              1               76             77                  1            76           77                   1                     76                   77

  Utzinger 1997 \[[@pntd.0008277.ref027]\]           0               83             83                               83           83                                         83                   83

  TOTAL                                              1,422           3,062          4,484               994          2,530        3,524                665                   2,010                2,675
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Exclusions {#sec019}
----------

A total of seven studies and four study arms were excluded for the following reasons. First, six studies were excluded as a whole, as they did not meet one or more of the inclusion criteria (two studies because the praziquantel dose was not 40 mg/kg \[[@pntd.0008277.ref020], [@pntd.0008277.ref028]\], and four studies because the duration of follow-up was \>60 days) \[[@pntd.0008277.ref005], [@pntd.0008277.ref018], [@pntd.0008277.ref029]\]. Second, we excluded study arms that were outside the set criteria, namely those who received a praziquantel dose higher or lower than 40 mg/kg \[[@pntd.0008277.ref013], [@pntd.0008277.ref014], [@pntd.0008277.ref022]\], or were outside the 0--14 years age range \[[@pntd.0008277.ref022]\]. Third, we excluded participants with *S*. *japonicum* infection because only one preschool-child was enrolled in Xu et al. \[[@pntd.0008277.ref030]\] out of six participants, and none in Olliaro et al. \[[@pntd.0008277.ref022]\] ([Table 1](#pntd.0008277.t001){ref-type="table"}).

The remaining 16 studies and study groups enrolled a total of 4,484 (63%) children who were treated with single 40 mg/kg oral praziquantel: preschool-age children (n = 1,422; 32%) and school-age children (n = 3,062; 68%). Of note, five studies \[[@pntd.0008277.ref011], [@pntd.0008277.ref015], [@pntd.0008277.ref022], [@pntd.0008277.ref027]\] did not enroll preschool-age children. Sousa-Figueiredo et al. \[[@pntd.0008277.ref025]\] enrolled both preschool- and school-age children aged 6--10 years, and Olliaro et al. \[[@pntd.0008277.ref022]\] included only school-age children aged 10--14 years ([Table 1](#pntd.0008277.t001){ref-type="table"}). Overall 75% of the treated children (n = 2,675) were followed up and had a measurable outcome 21--60 days post-treatment; 665 preschool-age children and 2,010 school-age children. More losses to follow-up occurred among the preschool-age children compared to their older counterparts (33% versus 21%, p \<0.001).

Out of the 16 studies included in the analyses, three were randomized controlled trials (RCT) and 13 were single-arm intervention or cohort studies. The RCTs were at low risk of selection bias with computer-generated block randomization, adequate allocation concealment, and blinding of either participants, personnel, or outcome assessment. The single-arm intervention or cohort studies were at unclear risk of bias as there was no randomization, no allocation concealment, and no blinding. Furthermore, no study mentioned if sampling was stratified for preschool- and school-age children. Regarding incomplete outcome data and selective reporting items of the risk of bias tables, attrition rate was generally low (Figs [2](#pntd.0008277.g002){ref-type="fig"} and [3](#pntd.0008277.g003){ref-type="fig"}). The funnel plots showed extensive publications bias (Figs [4](#pntd.0008277.g004){ref-type="fig"} and [5](#pntd.0008277.g005){ref-type="fig"}). However, for both *S*. *mansoni* and *S*. *haematobium*, half of the studies could not be plotted because they were non-comparative, hence a mean difference and a standard error of the mean between preschool- and school-age children could not be calculated (see also Figs [2](#pntd.0008277.g002){ref-type="fig"} and [3](#pntd.0008277.g003){ref-type="fig"}).

![*S*. *mansoni* studies forest plot of mean egg counts and bias table.](pntd.0008277.g002){#pntd.0008277.g002}

![*S*. *haematobium* studies forest plot of mean egg counts and bias table.](pntd.0008277.g003){#pntd.0008277.g003}

![Studies funnel plot for *S*. *mansoni*.](pntd.0008277.g004){#pntd.0008277.g004}

![Studies funnel plot for *S*. *haematobium*.](pntd.0008277.g005){#pntd.0008277.g005}

Of the 2,010 evaluable school-age children, 988 were aged 6 to \<10 years (382 (56%) presenting with *S*. *mansoni* and 301 (44%) with *S*. *haematobium* infections), and 1,022 were aged 10--14 years (667 (33%) *S*. *mansoni* and 1,343 (67%) *S*. *haematobium* infections) ([Table 3](#pntd.0008277.t003){ref-type="table"}). Intensity of infection at baseline and treatment outcomes expressed as ERRs calculated as AM as well as CRs are presented in [Table 4](#pntd.0008277.t004){ref-type="table"}, stratified by *Schistosoma* species for the three age groups (details by study in Supplementary Tables [2](#pntd.0008277.t002){ref-type="table"} and [3](#pntd.0008277.t003){ref-type="table"}, stratified by *Schistosoma* species). The baseline intensity of infection analyses adjusted on study and sex showed a significant difference between age groups with higher counts in the school- than the preschool-age children ([Fig 6](#pntd.0008277.g006){ref-type="fig"}, [S4 Table](#pntd.0008277.s004){ref-type="supplementary-material"}, [S4 Table](#pntd.0008277.s004){ref-type="supplementary-material"}, [S5 Table](#pntd.0008277.s005){ref-type="supplementary-material"}, and [S6 Table](#pntd.0008277.s006){ref-type="supplementary-material"}). A significant difference in baseline egg counts between boys and girls was found for *S*. *haematobium* but not for *S*. *mansoni* ([S6 Table](#pntd.0008277.s006){ref-type="supplementary-material"}). The age distribution of participants by *Schistosoma* species can be found in [S2 Fig](#pntd.0008277.s012){ref-type="supplementary-material"}.

![Baseline intensity of infection analyses adjusted for study and age.](pntd.0008277.g006){#pntd.0008277.g006}

10.1371/journal.pntd.0008277.t003

###### Number of subjects analyzed (evaluable subjects with follow-up) by age category and *Schistosoma* species.
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                                                     *S*. *mansoni*   *S*. *haematobium*   All                                     
  -------------------------------------------------- ---------------- -------------------- ----- ------- ----- ------- ----- ----- -------
  Coulibaly 2011 \[[@pntd.0008277.ref012]\]          35               0                    0     18      0     0       53    0     0
  Coulibaly 2017 \[[@pntd.0008277.ref013]\]          38               22                   20    0       0     0       38    22    20
  Coulibaly 2018 \[[@pntd.0008277.ref014]\]          0                0                    0     37      25    12      37    25    12
  Garba 2007 \[[@pntd.0008277.ref015]\]              0                99                   82    0       211   157     0     310   239
  Garba 2009 \[[@pntd.0008277.ref015]\]              0                0                    0     0       177   170     0     177   170
  Garba 2013 \[[@pntd.0008277.ref016]\]              88               0                    0     161     0     0       231   0     0
  Garba 1996 \[[@pntd.0008277.ref017]\]              0                0                    0     61      85    75      61    85    75
  Mutapi 2010 \[[@pntd.0008277.ref019]\]             0                0                    0     21      115   34      21    115   34
  Campagne, 2008 \[[@pntd.0008277.ref011]\]          0                0                    0     0       30    60      0     30    60
  Olds, 1999 \[[@pntd.0008277.ref021]\]              0                0                    0     2       49    67      2     49    67
  Olliaro 2007 \[[@pntd.0008277.ref022]\]            0                0                    190   0       0     0       0     0     190
  Raso 2004 \[[@pntd.0008277.ref023]\]               4                12                   22    0       0     0       4     12    22
  Scherrer 2007 \[[@pntd.0008277.ref024]\]           6                22                   21    0       0     0       6     22    21
  Sousa-Figueiredo 2012 \[[@pntd.0008277.ref025]\]   211              94                   0     0       0     0       211   94    0
  Stete 2010 \[[@pntd.0008277.ref026]\]              0                0                    0     1       20    56      1     20    56
  Utzinger 1997 \[[@pntd.0008277.ref027]\]           0                27                   56    0       0     0       0     27    56
  TOTAL                                              382              276                  391   301     712   631     665   988   1,022
  Preschool-age (0 to \<6 years)                     382                                         301                   665         
  School-age (6 to 14 years)                                          667                        1,343         2,010               

10.1371/journal.pntd.0008277.t004

###### Intensity of infection at baseline and follow-up, and treatment outcomes expressed as arithmetic mean (AM) egg reduction rate (ERR), cure rate (CR), and mean individual egg reduction rate (all with 95% confidence intervals) by age category and by *Schistosoma* species.
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  Age category             Follow-up duration (in days)   N evaluable   Mean EPG at baseline   Mean EPG at follow-up   ERR 95%CI              CR 95%CI               Mean individual ERR 95%CI
  ------------------------ ------------------------------ ------------- ---------------------- ----------------------- ---------------------- ---------------------- ---------------------------
  ***S*. *mansoni***                                                                                                                                                 
  0 to \<6 years           21                             290           244.4                  51.2                    79.1 (67.8; 88.6)      59.7% (54.0%; 65.3%)   48.8 (23.3; 74.3)
  0 to \<6 years           42                             92            109.6                  7.5                     93.2 (89.5; 96.3)      76.1% (67.4%; 84.8%)   81.1 (70.5; 91.8)
  6 to \<10 years          21                             138           226.4                  23.7                    89.5 (78.3; 96.3)      71.7% (64.2%; 79.3%)   78.2 (60.8; 95.7)
  6 to \<10 years          42                             138           100.6                  26.1                    74.1 (65.3; 82.1)      59.4% (51.2%; 67.6%)   64.1 (43.1; 85.1)
  10 to 14 years           21                             231           21.8                   0.8                     96.3 (93.2; 98.8)      87.9% (83.7%; 92.1%)   91.6 (84.2; 99.0)
  10 to 14 years           42                             160           114.4                  15.0                    86.9 (79.1; 93.3)      66.3% (58.9%; 73.6%)   81.9 (72.3; 91.4)
  6 to 14 years            21                             369           98.3                   9.4                     90.5 (81.0; 96.3)      81.8% (77.9%; 85.8%)   93.5 (91.3; 95.7)
  6 to 14 years            42                             298           108.0                  20.1                    81.4 (75.4; 86.4)      63.1% (57.6%; 68.6%)   83.4 (79.9; 86.9)
  ***S*. *haematobium***                                                                                                                                             
  0 to \<6 years           21                             56            20.0                   0.3                     98.4 (96.7; 99.5)      82.1% (72.1%; 92.2%)   94.9 (89.6; 100.2)
  0 to \<6 years           42                             184           37.0                   5.2                     85.9 (69.1; 98.8)      83.7% (78.4%; 89.0%)   93.9 (90.8; 96.9)
  0 to \<6 years           60                             61            14.9                   22.4                    -50.4 (-147.3; 34.1)   54.1% (41.6%; 66.6%)   75.7 (65.5; 86.0)
  6 to \<10 years          21                             222           95.0                   1.9                     98.1 (97.1; 98.8)      57.2% (50.7%; 63.7%)   95.6 (93.7; 97.5)
  6 to \<10 years          42                             405           76.7                   17.0                    77.9 (67.0; 88.3)      72.1% (67.7%; 76.5%)   92.7 (90.5; 94.9)
  6 to \<10 years          60                             85            79.1                   66.5                    15.9 (-37.2; 56.0)     22.4% (13.5%; 31.2%)   59.6 (50.0; 69.2)
  10 to 14 years           21                             238           97.2                   5.6                     94.2 (88.9; 98.0)      56.7% (50.4%; 63.0%)   93.4 (90.9; 95.8)
  10 to 14 years           42                             318           87.5                   24.3                    72.2 (58.1; 83.9)      67.9% (62.8%; 73.1%)   91.3 (88.8; 93.9)
  10 to 14 years           60                             75            81.4                   35.1                    57.0 (37.9; 73.1)      25.3% (15.5%; 35.2%)   61.5 (52.2; 70.9)
  6 to 14 years            21                             460           96.1                   3.8                     96.0 (93.1; 98.1)      57.0% (52.4%; 61.5%)   94.4 (92.9; 96.0)
  6 to 14 years            42                             723           81.5                   20.2                    75.2 (67.6; 82.8)      70.3% (66.9%; 73.6%)   92.1 (90.5; 93.7)
  6 to 14 years            60                             160           80.2                   51.7                    35.5 (9.1; 57.3)       23.8% (17.2%; 30.3%)   60.5 (53.8; 67.2)

The AM-ERRs are also presented graphically as forest plots in Figs [7](#pntd.0008277.g007){ref-type="fig"} and [8](#pntd.0008277.g008){ref-type="fig"} for *S*. *mansoni* and *S*. *haematobium*, respectively against the ≥95% WHO threshold for efficacy \[[@pntd.0008277.ref036]\]. Overall, 6/13 (2/6 for *S*. *mansoni* and 4/7 for *S*. *haematobium*) of the study groups with participants in the age-group under 6 years (preschool-age) met the WHO efficacy threshold, compared to 5/14 (1/6 for *S*. *mansoni* and 4/8 for *S*. *haematobium*) of the children aged 6 to \<10 years and 2/14 (0/6 for *S*. *mansoni* and 2/8 for *S*. *haematobium*) of the children aged 10--14 years).

![Forest plots of ERR for *S*. *mansoni*.](pntd.0008277.g007){#pntd.0008277.g007}

![Forest plots of ERR for *S*. *haematobium*.](pntd.0008277.g008){#pntd.0008277.g008}

The centile distribution of the individual-patient ERRs is displayed in Figs [9](#pntd.0008277.g009){ref-type="fig"} and [10](#pntd.0008277.g010){ref-type="fig"} for *S*. *mansoni* and *S*. *haematobium*, respectively.

![Centile distribution of the individual-patient ERRs for *S*. *mansoni*.](pntd.0008277.g009){#pntd.0008277.g009}

![Centile distribution of the individual-patient ERRs for *S*. *haematobium*.](pntd.0008277.g010){#pntd.0008277.g010}

The percentage of patients with ERRs = 0 (no decrease), between \>0 and \<100%, and 100% (corresponding to the CR) in the different age categories is represented in the bar graphs for each study and in [Table 5](#pntd.0008277.t005){ref-type="table"}.

10.1371/journal.pntd.0008277.t005

###### Individual patient egg reduction rate (ERR) by *Schistosoma* species and age group.

![](pntd.0008277.t005){#pntd.0008277.t005g}

                          *S*. *mansoni*   *S*. *haematobium*          
  ----------------- ----- ---------------- -------------------- ------ ---------
  0 to \<6 years    0%    39               10.2                 19     6.3
  0\<ERR\<100       100   26.2             49                   16.3   
  100%              243   63.6             233                  77.4   
  6 to \<10 years   0%    20               7.3                  44     6.2
  0\<ERR\<100       75    27.2             230                  32.3   
  100%              181   65.6             438                  61.5   
  10 to 14 years    0%    14               3.6                  34     5.4
  0\<ERR\<100       68    17.4             227                  36.0   
  100%              309   79.0             370                  58.6   
  Χ^2^ p-value                             \<0.001                     \<0.001
  6 to 14 years     0%    34               5.1                  78     5.8
  0\<ERR\<100       143   21.4             457                  34.0   
  100%              490   73.5             808                  60.2   
  Χ^2^ p-value                             \<0.001                     \<0.001

A majority of ERRs are in the 100% category (i.e. 'cured\' from the current infection). For preschool-age children as well as younger school-age children (aged 6 to 10 years) almost 80% of the subjects have an ERR above 70%, whereas the results per studies are highly hetegeneous in the 10--14 years old for both *S*. *mansoni* and *S*. *haematobium* as ascertained by the very different cumulative curves. There was a significant difference between age groups (p \<0.001) for both species, though for different reasons: for *S*. *mansoni* the difference is driven by preschool-age children having about twice as many non-responders as school-age children (10.2% versus 5.1%), while for *S*. *haematobium* more preschool-age children were cured (100% ERR: 77.4% versus 60.2%). However, no age difference was seen in treatment outcomes after multivariable adjustment in statistical models. The general linear model of individual-participant ERR with baseline log-transformed egg count as covariate and study, age, and sex as fixed variables did not show any difference in efficacy between age categories in the post-hoc pairwise comparisons of marginal means (least squares means) for either *S*. *mansoni* or *S*. *haematobium* ([Table 6](#pntd.0008277.t006){ref-type="table"}). This was confirmed in a mixed model employing a random effect for each study ([Table 7](#pntd.0008277.t007){ref-type="table"}). Neither baseline egg counts nor duration of follow-up influenced treatment outcome ([S7 Table](#pntd.0008277.s007){ref-type="supplementary-material"} and [S8 Table](#pntd.0008277.s008){ref-type="supplementary-material"}). Sensitivity analyses with log-transformed baseline egg counts for both *S*. *mansoni* and *S*. *haematobium* provided similar results for studies accounted for either as fixed factor (general linear model, [S4 Table](#pntd.0008277.s004){ref-type="supplementary-material"}) or as random effect (mixed model, [S5 Table](#pntd.0008277.s005){ref-type="supplementary-material"}).

10.1371/journal.pntd.0008277.t006

###### Post-hoc pairwise comparisons between age categories, general linear model.

![](pntd.0008277.t006){#pntd.0008277.t006g}

                                                                         *S*. *mansoni individual egg reduction rates*   *S*. *haematobium individual egg reduction rates*                              
  -------------------------- --------------------- --------------------- ----------------------------------------------- --------------------------------------------------- ------- --------- -------- -------
  **Age**                    **10 to 14 years**                          0.937                                           0.0224                                                      0.892     0.0134   
                             **6 to \<10 years**                         0.925                                           0.0205                                                      0.903     0.0130   
                             **0 to \<6 years**                          0.884                                           0.0238                                                      0.929     0.0203   
  **Age**                    **6 to 14 years**                           0.930                                           0.0162                                                      0.898     0.0113   
                             **0 to \<6 years**                          0.887                                           0.0223                                                      0.928     0.0202   
  **Pairwise comparisons**                                                                                                                                                                              
  **Age**                    **10 to 14 years**    **6 to \<10 years**   0.0119                                          0.0280                                              0.906   -0.0106   0.0134   0.710
                             **10 to 14 years**    **0 to \<6 years**    0.0533                                          0.0372                                              0.324   -0.0368   0.0273   0.368
                             **6 to \<10 years**   **0 to \<6 year**     0.0414                                          0.0288                                              0.322   -0.0262   0.0266   0.585
  **Age**                    **6 to 14 years**     **0 to \<6 years**    0.0432                                          0.0285                                              0.130   -0.0304   0.0260   0.243

10.1371/journal.pntd.0008277.t007

###### Post-hoc pairwise comparisons between age categories, mixed model.

![](pntd.0008277.t007){#pntd.0008277.t007g}

  -------------------------- --------------------- --------------------- --------------------------------------------------- ------------------------------------------------------- ----------- ---------- --------- -----------
                                                                         ***S*. *mansoni individual egg reduction rates***   ***S*. *haematobium individual egg reduction rates***                                    
  **Effect**                 **Category**                                **Mean**                                            **SD**                                                  **Adj P**   **Mean**   **SD**    **Adj P**
  **Age**                    **10 to 14 years**                          0.931                                               0.03744                                                             0.8902     0.04094    
  ** **                      **6 to \<10 years**                         0.913                                               0.03679                                                             0.9006     0.04083    
  ** **                      **0 to \<6 yeras**                          0.875                                               0.03796                                                             0.9292     0.04367    
  **Age**                    **6 to 14 years**                           0.922                                               0.03501                                                             0.8957     0.0403     
                             **0 to \<6 years**                          0.879                                               0.03779                                                             0.9284     0.04363    
  **Pairwise comparisons**                                                                                                                                                                                             
  **Age**                    **10 to 14 years**    **6 to \<10 years**   0.0172                                              0.0272                                                  0.802       -0.0105    0.0134    0.715
                             **10 to 14 years**    **0 to \<6 years**    0.0558                                              0.0344                                                  0.236       -0.0390    0.0265    0.306
                             **6 to \<10 years**   **0 to \<6 years**    0.0386                                              0.0275                                                  0.341       -0.0285    0.0259    0.512
  **Age**                    **6 to 14 years**     **0 to \<6 years**    0.0423                                              0.0269                                                  0.117       -0.0327    0.0253    0.170
  -------------------------- --------------------- --------------------- --------------------------------------------------- ------------------------------------------------------- ----------- ---------- --------- -----------

Safety was reported in 7/16 studies with only four studies \[[@pntd.0008277.ref013], [@pntd.0008277.ref016], [@pntd.0008277.ref019], [@pntd.0008277.ref035]\] reporting on evaluable patients who had safety data corresponding to participants with follow-up \<60 days, age ≤14 years, and praziquantel dose of 40 mg/kg (total number assessed on day 1 = 1,128; at follow-up = 1,065, 94%) ([Table 8](#pntd.0008277.t008){ref-type="table"}). Overall, 226 (20%) patients suffered from at least one AE 4 hours after drug intake, 88 (8%) after 24 hours, and 33 (3%) at the treatment follow-up, respectively. At least one AE was experienced at 4 hours post-treatment by 19% and 44% of under 6-year-old children and children aged 10--14 years, respectively. Only one child had an AE in the 6- to \<10-year-old age group. The relative proportions at 24 hours were 5%, 21%, and 0%. At follow-up, 10% of the children aged 10--14 years reported at least one AE, and none in the other age-groups.

10.1371/journal.pntd.0008277.t008

###### Number of children treated with a single 40 mg/kg oral dose of praziquantel reporting adverse events (AEs) and number of AEs by age group.

![](pntd.0008277.t008){#pntd.0008277.t008g}

                                                        0 to \<6 years   6 to \<10 years   10 to 14 years   All                       
  --------------------------------- ------------------- ---------------- ----------------- ---------------- ----- ----- ----- ------- -----
  Day 0 (4 hours post-treatment)    Experienced ≥1 AE   81               19%               1                0%    144   44%   226     20%
                                    Number of AEs       81               22%               1                0%    288   78%   370     
                                    Number evaluated    416                                381                    331         1,128   
  Day 1 (24 hours post-treatment)   Experienced ≥1 AE   19               5%                                       69    21%   88      8%
                                    Number of AEs       19               7%                                       253   93%   272     
                                    Number evaluated    416                                381                    331         1128    
  Day 21                            Experienced ≥1 AE                                                             33    10%   33      3%
                                    Number of AEs                                                                 134   1     134     
                                    Number evaluated    372                                376                    317         1070    

A total of 370, 272, and 134 AEs were reported on the day of treatment 4 hours after drug intake, at 24 hours post-treatment, and at the follow-up visit, respectively. At 4 hours, there were 81 AEs of mild intensity in children aged 0 to \<6 years; one mild in the age group 6 to \<10 years; and 228 mild, 159 moderate, and one severe AEs in children aged 10--14 years. At 24 hours, 19 mild AEs in the 0 to \<6 year age group; none in the children aged 6 to \<10 years; and 205 mild, 46 moderate, and two severe AEs in the oldest group of children 10--14 years. At treatment follow-up, a total of 88 mild and 46 moderate AEs were observed in the 10- to 14-year-old age group. The severe AEs were dizziness, anorexia, and diarrhea, but none of the AEs were judged as serious.

At 4 hours post-treatment, the most frequent AE was abdominal pain (39.7% of AEs), followed by diarrhea (14.3%), vomiting (9.5%), headache and dizziness (both 8.4%). At 24 hours, it was headache (23.2%) then abdominal pain (16.5%), dizziness (15.1%), and diarrhea (11%). At treatment follow-up, headache (27.6%), abdominal pain (19.4%), anorexia (14.2%), and dizziness (12.7%) were the most frequent AEs.

Discussion {#sec020}
==========

This individual-participant data meta-analysis aimed to assess whether a single 40 mg/kg oral dose of 40 mg/kg of praziquantel administered to preschool-age children (aged \<6 years) would be as efficacious and safe as in school-age children. This kind of evidence is important. Indeed, while the current emphasis of preventive chemotherapy is on school-age children \[[@pntd.0008277.ref001], [@pntd.0008277.ref034]\], preschool-age children are now also recognized to carry a significant burden of disease, and hence, they are becoming a target for preventive chemotherapy, especially if a pediatric formulation of praziquantel becomes available \[[@pntd.0008277.ref006], [@pntd.0008277.ref007]\]. Furthermore, efforts are under way to strategically move from morbidity control to elimination, which means preventive chemotherapy might need to be expanded to include all age-groups in order to remove all untreated reservoirs of infection that contribute to ongoing local transmission \[[@pntd.0008277.ref040]\].

Taken together, our results point to no age-effect on treatment efficacy with the standard single-dose of 40 mg/kg praziquantel, whether administered to children under the age of 6 years (preschool-age), or to school-age children (aged 6--14 years), or whether the latter group is further broken down into 6 to less than 10, and 10 through 14 years (as some studies only included either age-group).

We analyzed data using two models: (i) a general linear model with or without baseline log-transformed *Schistosoma* egg counts as covariate and study, age, and sex as cofactors; and (ii) a mixed model with or without baseline log-transformed egg counts as covariate, age as a fixed factor, with a random effect for each study. None of these models detected a statistically significant difference in the individual ERRs between age categories. These analyses also show that the lower baseline egg counts found in preschool-age children did not have an effect on treatment outcome, nor did duration of follow-up within the 21--60 day time-frame.

Our conclusions are further supported by the observation that, when using the WHO-recommended AM-ERR, there is no indication that fewer groups composed of preschool-age children meet the WHO ≥95% efficacy threshold compared to school-age children. These results are in overall agreement with mixed-effect multivariate analysis of aggregated data that found no significant difference between preschool- and school-age children for CR or geometric mean ERR for either *S*. *mansoni* or *S*. *haematobium* after controlling for time of assessment, formulation, intensity of infection, and diagnostic approach \[[@pntd.0008277.ref041]\]. While host factors, like age-related differences in drug metabolizing activity \[[@pntd.0008277.ref042]\] might play a role in praziquantel metabolism and overall efficacy, increasing the dose to 60 mg/kg may not lead to better efficacy. Two of the studies conducted in Côte d'Ivoire contributing to this analysis, which also studied the response to placebo and doses ranging from 20 mg/kg to 60 mg/kg, showed a flat dose-response curve in both preschool- and school-age children infected with *S*. *haematobium* and preschool-children infected with *S*. *mansoni* \[[@pntd.0008277.ref013], [@pntd.0008277.ref014]\]. Another study \[[@pntd.0008277.ref022]\] compared 40 mg/kg to 60 mg/kg in children aged 10--14 years, and did not find a difference either. Similarly, in an aggregated-data meta-analysis using a random-effect meta-analysis regression model, a dose-effect for CR was found up to 40 mg/kg for *S*. *mansoni* and 30 mg/kg for *S*. *haematobium* with no benefit in increasing the dose, in school-age children \[[@pntd.0008277.ref043]\].

Treatment with a single 40 mg/kg oral dose of praziquantel was well tolerated, especially in preschool-age children who experienced fewer and generally only mild AEs when compared to school-age children. Previous systematic reviews pertaining to the efficacy and safety of praziquantel for schistosomiasis already showed that praziquantel is safe and AEs usually mild and self-limiting \[[@pntd.0008277.ref041], [@pntd.0008277.ref044], [@pntd.0008277.ref045]\]. It is, however, conceivable that this is a result of underreporting by younger children, if AEs were not specifically and proactively elicited.

Our study has several limitations. First, out of 16 studies included in the analysis, 13 were single-arm thus with an unclear risk of bias concerning selection of participants. Second, the studies enrolled selectively different age groups, so we used the principles of network meta-analysis to compare participant outcomes in different groups, which were not necessarily enrolled at the same site and time, and might thus not be comparable. Third, safety and tolerability at large were also generally underreported. Fourth, no information is available for S. *japonicum*. A more general methodological issue is the limitations of counting eggs in excreta in young children, and the imperfect correlation between egg shedding and worm burden, which would be better reflected by antigen-detection methods. \[[@pntd.0008277.ref046]\] However, the significance and comparability of results of efficacy studies based on antigen-detection methods vis-à-vis direct egg-detection remains unclear.

In conclusion, based on the data presented here, there is no indication that preventive chemotherapy with single-dose 40 mg/kg praziquantel would be less efficacious and tolerated in preschool-age children than it is in school-age children. However, these conclusions are drawn from an available, limited body of evidence, which is only a tiny fraction of the overall use of praziquantel, with only a few studies designed for direct comparisons between age groups. Whether and when preschool-age children will be exposed systematically to preventive chemotherapy, close monitoring of efficacy as well as safety will be required. This in particular considering preschool-age children have about twice as high rates of non-responders in the individual-patient ERR analysis than older children.

It should also be noted that the WHO-recommended 95% ERR threshold was not met in many studies, which calls for improved dosing and delivery strategies.
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Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: Did all studies deliver praziquantel to the PSACs in the same way - whole tablet, crushed tablet in juice?

Were all treatments accompanied by food ? If not, did this have an impact on adverse events?

Was the praziquantel used in the studies all from the same source / manufacturer?

I see little value including S. japonicum due to the stated absence of data.

Reviewer \#2: A very clear statistical analysis from a well-organised database of IPD.

Reviewer \#3: General

1\) Were PRISMA guidelines used for this Meta-analysis. Not referenced in methods. You provide the flow diagram but should reference in methods.

2\) Regarding S. japonicum, there is only ONE PSAC subjects across all studies. One PSAC in China, none in Philippines. How is this useful for meta with focus on treatment safety and efficacy in PSAC??? At the very least references to S. japonicum should be removed from abstract and other places.

3\) in many tables the close brackets \[ \] is left open \[ \[ for many age groups

5\) In methods, please clarify what was asked regarding AEs at follow up. Did you ask about current AE due to the (weeks preceding) treatment or recall of AE in day or so after?

6\) Methods do not approach whether studies referenced repeating dose if vomiting occurred or rates of refusal among young children. Although some studies likely didn't collect, one can still add to discussion regarding ways to improve overall ERR for all children. See point 6 above. Lines 153-55. It is not clear here whether you are referring to reporting bias (participant attribute) or publication bias. These lines seem to apply to the latter.

Specific

Line 164-spell out AM-ERR with first use

Line 233- as worded it is not clear how you are supporting lack of different types of bias:

"The RCTs were at low risk of selection bias with computer-generated block randomization, adequate allocation concealment, and blinding of either participants, personnel, or outcome assessment."

Some of these procedures do not support "selection bias"

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: OK

Reviewer \#2: Some excellent graphs showing novelty in visualization of complex data.

Reviewer \#3: See general comments on S. japonicum

Lines 310-12

This sentence is not clear:

At least one AE was experienced at 4 hours post-treatment by 19% and 44% of under 6-year-old children and children aged 10-14 years, respectively.

Table 6

Please provide clearer title and column headings to denote what the "mean" represents

Figure 6 -- need to clarify what different colors represent in the bar graph. Large number of low ERR in one study? As above, this also needs to be discussed. Neither the figure legend nor results text explain this figure at all adequately.

In many tables the close brackets \[ \] is left open \[ \[ for many age groups

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: OK

Reviewer \#2: Large true but I think the authors should elaborate a bit more on the following:

Egg count is not the \'best\' measure of cure in young children (since there is an unusual dynamic across time of first infection and age towards patency (see <https://www.ncbi.nlm.nih.gov/pubmed/21245910>). I realize that egg-count is important in SAC dynamics but some awareness of this non-linear effect in PSAC is important.

By that same token a bit more should be made of antigen biomarkers (either CAA in sera/urine or CCA in urine).

Collectively I expect the use of biomarkers would show less efficacy, and note that the paediatric praziquantel consortium (on the basis of their trials) is adopting 50 mg/kg of the L-PZQ (given inferiority/superiority measures).

The future adoption of a mono-isomeric form in PSAC somewhat changes the present guidance that this current script offers. It does support however the WHO-stop gap of using crushed racemate in this age class. From the results presented here seems to be a sensible altrnative way forward more immediate to the L-PZQ (which might need testing in SAC?).

Reviewer \#3: Lines 340-1- same issue on emphasis on formulation. Most of your included studies used crushed tablets

Lines 365-

Discussion focuses too heavily on lack of difference in other studies at 60 mg/kg. Though you show that the ERR not significantly different between age groups at 40 mg/kg, there is not discussion of the fact that most studies did not find ERR at or above WHO recommended 95% threshold. This must be discussed. There are other reasons besides dose provided that may explain including different dosing strategies (larger total dose over more time to improve tolerability, formulations that might improve drug delivery based on tolerability, absorption etc.

Also, at some point in the discussion, particularly when you reference issue of higher doses to 60 mg/kg, must state that much less is known about this in S. japonicum.

Here or elsewhere, must discuss the almost double rate of ERR less than 0% in S. mansoni among PSAC. This can be included in above regarding adequacy of ANY current does.

Lines379+ - must include in limitations that you cannot say anything about comparing efficacy of 40 mg/kg among PSAC and school age for S. japonicum. That gets lost entirely.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: Apart from the comments above \"Accept\"

Reviewer \#2: NA

Reviewer \#3: Methods

Lines 153-55. It is not clear here whether you are referring to reporting bias (participant attribute) or publication bias. These lines seem to apply to the latter.

Line 164-spell out AM-ERR with first use

Line 233- as worded it is not clear how you are supporting lack of different types of bias:

"The RCTs were at low risk of selection bias with computer-generated block randomization, adequate allocation concealment, and blinding of either participants, personnel, or outcome assessment."

Some of these procedures do not support "selection bias"

Results

Lines 310-12

This sentence is not clear:

At least one AE was experienced at 4 hours post-treatment by 19% and 44% of under 6-year-old children and children aged 10-14 years, respectively.

Discussion

Lines 340-1- same issue on emphasis on formulation. Most of your included studies used crushed tablets

Lines 365-

Discussion focuses too heavily on lack of difference in other studies at 60 mg/kg. Though you show that the ERR not significantly different between age groups at 40 mg/kg, there is not discussion of the fact that most studies did not find ERR at or above WHO recommended 95% threshold. This must be discussed. There are other reasons besides dose provided that may explain including different dosing strategies (larger total dose over more time to improve tolerability, formulations that might improve drug delivery based on tolerability, absorption etc.

Also, at some point in the discussion, particularly when you reference issue of higher doses to 60 mg/kg, must state that much less is known about this in S. japonicum.

Here or elsewhere, must discuss the almost double rate of ERR less than 0% in S. mansoni among PSAC. This can be included in above regarding adequacy of ANY current does.

Lines379+ - must include in limitations that you cannot say anything about comparing efficacy of 40 mg/kg among PSAC and school age for S. japonicum. That gets lost entirely.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: The limitations of the study have been addressed by the authors. This is a most useful analysis of data considered in previously published papers and highlights that treatment of PSACs with praziquantel has a similar benefits to treatment of older children.

Reviewer \#2: A useful script - secondary analysis - competently done. For brevity I think it could be shortened a little will a few more specific pointers on \'grey\' areas (mono-isomer v racemate) where future impact might be less than expected.

Reviewer \#3: 1) Were PRISMA guidelines used for this Meta-analysis. Not referenced in methods. You provide the flow diagram but should reference in methods.

2\) Regarding S. japonicum, there is only ONE PSAC subjects across all studies. One PSAC in China, none in Philippines. How is this useful for meta with focus on treatment safety and efficacy in PSAC??? At the very least references to S. japonicum should be removed from abstract and other places.

3\) introduction Lines 97-101: Same issue on waiting for other formulation. You cite the WHO report of 2010 on this which actually states in the executive summary:

"Studies on the treatment of preschool-age children conducted in these five countries (n=3198) among children aged 1 month to 7 years showed that praziquantel in a tablet or suspension formulation was safe and effective against schistosomiasis, and acceptable...The two studies in Mali and Uganda that compared suspension and tablets found no difference in cure rates between the two formulations. In Uganda, there was also no difference in rates of egg reduction between the two formulations."

This is not simply an issue of semantics; the way this manuscript reads strongly implies that we must await pediatric formulations which will do harm to young children who can take crushed tablets. Even your PICOS statement addresses efficacy of 40 mg/kg dose as the primary goal of the study, without reference to dosing form which dominates abstract and introduction.

4\) Introduction Lines 99-101- at least one drug (Bayer) is "registered" (US FDA approved) down to age one so this should be modified accordingly.

4\) In methods, please clarify what was asked regarding AEs at follow up. Did you ask about current AE due to the (weeks preceding) treatment or recall of AE in day or so after?

5\) at some point in the discussion, particularly when you reference issue of higher doses to 60 mg/kg, must state that much less is known about this in S. japonicum.

6\) Discussion focuses too heavily on lack of difference in other studies at 60 mg/kg. Though you show that the ERR not significantly different between age groups at 40 mg/kg, there is not discussion of the fact that most studies did not find ERR at or above WHO recommended 95% threshold. This must be discussed. There are other reasons besides dose provided that may explain including different dosing strategies (larger total dose over more time to improve tolerability, formulations that might improve drug delivery based on tolerability, absorption etc.

7\) if any authors receive funding from pharmaceutical companies developing Pediatric formulations for Praziquantel, this should be disclosed.

8\) for S. mansoni, there were double the number of children who had ERR 0%. This is never discussed and provides good topic for discussion under tolerability issues in this age group. Did they vomit the dose/refuse?

9\) Methods do not approach whether studies referenced repeating dose if vomiting occurred or rates of refusal among young children. Although some studies likely didn't collect, one can still add to discussion regarding ways to improve overall ERR for all children. See point 6 above.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Data Requirements:

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-materials-and-methods>
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8 Apr 2020

Dear Vaillant,

We are pleased to inform you that your manuscript \'Efficacy and safety of single 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: an individual participant data meta-analysis\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Antonio Montresor

Guest Editor

PLOS Neglected Tropical Diseases

Timothy Geary

Deputy Editor

PLOS Neglected Tropical Diseases

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Thank you for addressing the points raised by the reviewers,

the manuscript is in my opinion suitable for publication
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Creative Commons Attribution License
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12 Jun 2020

Dear Vaillant,

We are delighted to inform you that your manuscript, \"Efficacy and safety of single 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: an individual participant data meta-analysis,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases
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